Skip to main content
PLOS One logoLink to PLOS One
. 2022 Oct 3;17(10):e0275423. doi: 10.1371/journal.pone.0275423

Identification of families in need of support: Correlates of adverse childhood experiences in the right@home sustained nurse home visiting program

Lynn Kemp 1,*, Tracey Bruce 1,#, Emma L Elcombe 1,#, Fiona Byrne 1,#, Sheryl A Scharkie 1,#, Susan M Perlen 2,#, Sharon R Goldfeld 2,3,4,#
Editor: Jianhong Zhou5
PMCID: PMC9529103  PMID: 36190969

Abstract

Background

Little is known about the efficacy of pregnancy screening tools using non-sensitive sociodemographic questions to identify the possible presence of as yet undiagnosed disease in individuals and later adverse childhood events disclosure.

Objectives

The study aims were to: 1) record the prevalence of risk disclosed by families during receipt of a sustained nurse home visiting program; and 2) explore patterns of relationships between the disclosed risks for their child having adverse experiences and the antenatal screening tool, which used non-sensitive demographic questions.

Design

Retrospective, observational study.

Participants and methods

Data about the participants in the intervention arm of the Australian right@home trial, which is scaffolded on the Maternal Early Childhood Sustained Home-visiting model, collected between 2013 and 2017 were used. Screening data from the 10-item antenatal survey of non-sensitive demographic risk factors and disclosed risks recorded by the nurse in audited case files during the subsequent 2 year intervention were examined (n = 348). Prevalence of disclosed risks for their child having adverse experiences were analysed in 2019 using multiple response frequencies. Phi correlations were conducted to test associations between screening factors and disclosed risks.

Results

Among the 348 intervention participants whose files were audited, 300 were noted by nurses to have disclosed risks during the intervention, with an average of four disclosures. The most prevalent maternal disclosures were depression or anxiety (57.8%). Mental health issues were the most prevalent partner and family disclosures. Screening tool questions on maternal smoking in pregnancy, not living with another adult, poverty and self-reporting anxious mood were significantly associated with a number of disclosed risks for their child having adverse experiences.

Conclusions

These findings suggest that a non-sensitive sociodemographic screening tool may help to identify families at higher risk for adverse childhood experiences for whom support from a sustained nurse home visiting program may be beneficial.

Introduction

Adverse childhood experiences (ACEs), such as exposure to child abuse, neglect and household dysfunction, are detrimental for child and adult health. Felitti [1] in a large population study noted linear relationships between adults’ recollection of the number of ACEs they were exposed to, and adult health issues and mortality, with lifelong costs and consequences [24]. Recent research has shown that more proximal recall of ACEs has been associated with the prevalence of physical, mental and developmental health conditions in children and young people aged 0–17 years [2, 5].

Children’s exposure to ACEs is now seen as a priority public health issue and strategies to reduce exposure are needed. One suggested strategy is screening parents of very young children for ACEs [6]. Policies of screening for psychosocial risks have been implemented in Australia [7] and other countries [8]. There is evidence, however, that women find questioning about sensitive issues such as their own ACEs or current household dysfunction, particularly family violence and drug and alcohol issues, to be distressing [9], and for those with present risk, daunting and intrusive [9]. Some do not disclose risks as they do not think it would lead to help [8], or provide socially acceptable, rather than truthful, responses, and some do not disclose due to fear of stigma or negative consequences such as loss of child custody [10, 11]. For example, Johnson [12] suggested low rates of disclosure of alcohol and substance use may be the result of public awareness of the risk these pose in pregnancy and breastfeeding; and a qualitative study notes that ‘at least 20 per cent of those who experience IPV [intimate partner violence] tell no one else about it’ [13].

Consequently, WHO, whilst supportive of universal screening, does not advocate screening in all women. Rather WHO recommends screening in health care visits when factors known to be associated with ACEs are present, such as depression, self-harm or presence of an intrusive partner [14, 15]. However, this approach would require health care providers to have the opportunity to observe such factors. Surveillance within public health provision is complex with debates over practice and ethics, and the power relationships between clients and clinicians [16, 17]. Clinicians also find universal screening to be unfeasible in postpartum visits [18], and are uncomfortable with routine and standardized questioning about issues such as domestic violence and abuse; preferring to gather information in diverse ways such as ‘‘cloaking’ the assessment in the baby check and downplaying the assessment as ‘doing some paperwork” [9].

Privacy, a safe and confidential environment and a supportive relationship between the clinician and the client are needed for both inquiry and disclosure of ACEs [16, 18], with the latter necessarily absent in universal screening. There is evidence that when screening occurs in an established relationship parents feel more comfortable to provide honest information in the context of a strong working relationship [19]. For example, a study investigating the feasibility of implementing ACE screening of parents found that within the Early Head Start home visiting program group, prevalence of disclosed risk was considerably higher when screening occurred weeks or months into the program, compared to screening at first visit or having minimal contact [12].

A screening process is therefore needed that does not require disclosure of sensitive issues, but can ‘identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms. This can include individuals with presymptomatic or unrecognized symptomatic disease’ [14]. Little is known, however, of non-sensitive sociodemographic factors associated with ACE risks subsequently disclosed. A recent US study has suggested that birth certificate data such as acknowledgement of paternity and race may be useful to indicate risks for child maltreatment [20]. Prevention and early intervention programs such as sustained home visiting that commence in pregnancy have relied on bluntly targeting services to easily identifiable population categories, typically young, poor, first-time mothers. Evidence is emerging however, that the population prevalence of risk is not solely (or even largely) concentrated in these (or any) group [21, 22]. The challenge is therefore, ascertaining how prevention and early intervention services can screen and implement programs for families of children at risk of ACEs in ways that do not require them to disclose those risks in order to be considered eligible for the program.

In the context of the Australian right@home randomized controlled trial [23], a screening tool was developed to identify pregnant women who could potentially benefit from additional support to promote positive home environments for their children’s health and development and prevent or mitigate the children’s exposure to ACEs through receipt of the sustained nurse home visiting program. To facilitate trial recruitment, the screening tool needed to be deliverable in a non-private environment, the antenatal clinic waiting room, and was thus limited to asking non-sensitive questions. Piloting of the tool prior to commencement of the trial demonstrated that it was both feasible and acceptable [24], and was subsequently used as a tool for identifying eligible families for participation in the trial. The objective of this study is to explore risks that were disclosed by families throughout their receipt of the home visiting program and the correlation between these disclosed risks and the non-sensitive screening questions.

Methods

This observational cohort study was a secondary project based within the intervention arm of the right@home trial [23] to describe the prevalence of disclosed ACE risks and the correlation between specific sociodemographic characteristics in pregnancy and disclosed risk in the context of delivery of the right@home program to child age 2 years.

right@home program

The right@home program is a sustained nurse home visiting intervention structured around the Maternal Early Childhood Sustained Home-visiting (MECSH) model [2527] incorporating core content of child development parent education program, social support promotion and group activities with added content modules focussed on language development, parent-child attachment, healthy eating, child sleeping and home safety [23, 25, 28]. The program improved outcomes in parent care, parent responsivity and the home learning environment [28]. Postgraduate trained nurses delivered the program from the antenatal period until the child’s second birthday. The nurses were supported by a social care practitioner who provided instrumental and psychosocial support for families and assisted nurses and families to leverage community resources.

Sample

722 pregnant women were recruited to the right@home program trial between May 2013 and August 2014 [23, 28]. Eligible women were English speaking, resided within the seven study areas in Victoria and Tasmania Australia, and had two or more of the ten screening risk factors (see Table 1). Women of any age and with any number of children were eligible to participate in the right@home trial. 363 women were randomly allocated to the trial intervention arm, and 352 commenced the intervention program [28]. This secondary study used antenatal screening data and disclosed risk information for mothers who were allocated to the intervention arm of the trial and who received at least one nurse home visit, and whose files were audited (n = 348).

Table 1. Screening data from a 10 question survey: right@home intervention recipients (n = 352).

Screening risk factors, maternal report in pregnancy n (%)
Young pregnancy (age < 23 years) 90 (25.6%)
Not living with another adult 61 (17.3%)
No support in pregnancy (financial, emotional or practical) 31 (8.8%)
Poorer health (global health self-reported fair or poor [29]) 251 (71.3%)
Maternal smoking in pregnancy 115 (32.7%)
Long-term illness limiting daily living 72 (20.5%)
Anxious mood (very stressed, anxious, unhappy or difficulty coping in last 2 weeks, and moderately or a lot bothered by the feelings [30]) 102 (29.0%)
School < Year 12: non completion of secondary education in Australia 193 (54.8%)
Poverty (no income in household other than benefits and/or having a means-tested Health Care card) 123 (34.9%)
Never worked 63 (17.9%)

Data collection and management methods

Antenatal screening was conducted in antenatal clinic waiting rooms by the trial research assistants. At two points during the trial (mid-trial March 2016 and end-trial June 2017), nurses delivering the right@home program to families were asked to conduct a retrospective semi-structured case audit to document risks disclosed by participating mothers. The trial research team provided each nurse with a spreadsheet listing their clients and asked them to note any risks that had been disclosed using predefined drop-down menu categories. Open fields were also provided to capture any risks not in the menu. Information provided was reliant on the accuracy and quality of the records provided by the nurses: no independent audit was conducted and the data provided by the nurses was considered to be complete.

Post collection the text in the open fields was coded into categories by registered nurses in the research team. Multiple disclosures could be noted for each family, and included disclosure of risk associated with the participating mother, her partner and broader family. The coded categories (predefined and other) were summarized into the presence or absence of disclosure of the household challenges identified as contributing to ACEs by the UK 70/30 campaign [31]: domestic violence, substance abuse, mental illness, parental separation/divorce, and incarcerated parent. Engagement with the child protection system was coded as a proxy for child abuse and neglect.

Analysis

Prevalence of disclosed ACE risks was analysed in 2019 using multiple response frequencies using SPSS v24.0.0.1. Phi correlation coefficients and associated significance levels were to measure the association between the presence/absence of screening factors and presence/absence of disclosed ACE risks.

Trial registration

Trial registration number: ISRCTN89962120 (21/Aug/2013), retrospectively registered.

Compliance with ethical standards

Ethics approval

The right@home trial was approved by the Human Research Ethics Committees in Australia of: The Royal Children’s Hospital, Victoria (HREC 32296); Peninsula Health, Victoria (HREC/13/PH/14); Ballarat Health Services, Victoria (HREC/13/BHSSJOG/9); Southern Health, Victoria (HREC 13084X); Northern Health, Victoria (HREC P03/13); and The University of Tasmania (HREC H0013113). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written consent was obtained.

Results

No information was received from the nurses for four study participants, who ceased receipt of the intervention early in the program. Most study participants completed the intervention to their child’s second birthday (n = 304, 86.4%). The 348 participants in this study were noted by the nurses to have disclosed 969 maternal, 169 partner-related and 167 family related risks: a total of 1305 disclosures over the intervention duration. The mean number of disclosures per participant was four (range 0–16) with 48 participants (13.8%) noted by the nurses as disclosing no risks. The prevalence of risk disclosures categorized as ACEs is presented in Table 2. The most prevalent maternal disclosures were depression (n = 138, 39.4%) and anxiety (n = 120, 34.5%). The most prevalent partner and family disclosure was mental health issues (partner n = 74, 21.3%; family n = 65, 18.5%). Other disclosures not categorized into ACE risks included mother (n = 48), partner (n = 5) and infant (n = 11) physical health concerns, maternal grief (n = 9) and isolation (n = 24). Mothers also disclosed concerns in managing care of disabled or aged family members (n = 17) and financial stress (n = 42). No parental incarceration was recorded.

Table 2. Prevalence rates of each ACE risk factor disclosed: Nurse audited participants (n = 348).

ACE Risk Factors Disclosure n (%)
Maternal ACE risk factors
A. Substance misuse 37 (10.6%)
B. Domestic violence 61 (17.5%)
C. Engagement with child protection services for current children 69 (19.8%)
D. Anxiety or Depression 201 (57.8%)
E. Major mental health conditions (bipolar, eating, obsessive-compulsive, personality, post-traumatic stress and psychotic disorders) 34 (9.8%)
F. Any mental health condition (D+E) 219 (62.9%)
G. History of unstable relationships 62 (17.8%)
Family ACE risk factors
H. Family/Partner Substance misuse 65 (18.7%)
I. Family/Partner Domestic violence 15 (4.3%)
J. Family/Partner member with Mental health condition (including anxiety or depression or major mental health conditions) 120 (34.5%)
K. Family/Partner with History of unstable relationships 11 (3.2%)
Combined ACE risk factors
L. Any Substance Misuse (A+H) 80 (23.0%)
M. Any Domestic Violence (B+I) 73 (21.0%)
N. Any Mental health condition including anxiety or depression (D+E+J) 240 (69.0%)
O. Any History of unstable relationships (G+K) 68 (19.5%)
Number of ACE risk factors disclosed
0 80 (23.0%)
1 110 (31.6%)
2 86 (24.7%)
3 or more 72 (20.7%)

The correlations between the individual screening questions and mother, partner and family disclosed ACE risk is presented in Fig 1. Maternal smoking in pregnancy, not living with another adult, poverty, and self-reporting anxious mood were significantly associated with the disclosure of a large number of differing ACE risks, although all correlations were weak (less than 0.3). Not completing secondary education was associated with disclosure of partner or family substance misuse, but was also associated with significant non-disclosure of maternal anxiety, depression or mental health conditions.

Fig 1. Phi correlations of screening criteria by ACE risk disclosed to MECSH nurse.

Fig 1

Discussion

The lifelong costs and consequences of early life adversity necessitates early intervention to prevent or mitigate children’s exposure to the child abuse, neglect and household dysfunction that are associated with ACEs [3]. Being able to intervene early, however, is premised upon being able to identify those families where risks are present, and there is mounting evidence that reliance on universal screening and first or minimal contact disclosure of sensitive risks is failing to identify those facing adversity and in need of additional support. Knowledge of what non-sensitive characteristics in pregnancy are associated with families’ subsequent disclosure of sensitive risks could enable early identification of families in need of additional support and improve the early detection of issues that could lead to children experiencing ACEs. The right@home trial provided an opportunity to explore whether non-sensitive sociodemographic factors in pregnancy, which can be feasibly and acceptably detected through a screening tool administered in public spaces [24], are associated with disclosure of risks that could result in their child/ren having adverse experiences, so that effective early intervention programs can be implemented to improve outcomes.

Recruitment using the non-sensitive screening questionnaire identified an intervention population where ACE risks were highly prevalent. The prevalence in this study sample was considerably higher for all ACEs than the population prevalence reported by parents of children aged 0–17 as recorded by Bright [2], with the rate of disclosed risk more than double in this sample for substance misuse (23.0% cf 10.7%) and domestic violence exposure (21.0% cf 7.3%), and nearly seven times higher for mental health conditions (69.0% cf 9.1%), with 20.7% reporting having three or more ACEs compared with 10.3%. The rates disclosed over time in the right@home program were comparable with the risk profile at enrolment of home visiting clients reported in the US Maternal, Infant, and Early Childhood Home Visiting Program Evaluation (MIHOPE) [32] for substance misuse and domestic violence, but reported rates for depression were much higher than the MIHOPE rate of 30% at enrolment. The right@home rates were considerably higher than those disclosed in screening at three months post enrolment in the Healthy Families America home visiting program HELP study (for example, the HELP study reported a screening prevalence of 13% for maternal depression and 11% for intimate partner [domestic] violence) [10].

The variance in the population rates and those disclosed in other studies can likely be attributed to differences in the timing of and tools used for screening, and this current study did not seek information on whether the disclosed risk was validated through clinical measurement. The retrospective clinical audit used to identify disclosed risks only captured those that were documented in client notes, and may not therefore include all, or minor issues that were not considered as needing to be recorded, and may still underestimate the prevalence of risk. Uniquely this study captured disclosure of risk at any time over the more than two year right@home program intervention with each family. The high risk prevalence may thus be a more accurate picture of the ACE environment for young children in adversity than screening, which provides point prevalence only, or retrospective parental/adult recall such as used in the original ACEs study [1] or the more recent study of parents of children aged 0–17 [2]. Home visiting over a sustained period of time enables practitioners to establish and develop effective trusting therapeutic relationships with parents [33], which may support disclosure.

Importantly, the non-sensitive screening questionnaire identified this high risk population, and also identified a maternal population where the risk was sited with the partner or family, rather than the mother. For example, disclosure of substance misuse was more likely associated with partner or family than with the mother. Understanding of the prevalence of disclosed partner and family risk is needed as these contribute to the overall setting for children’s experiences and can contribute to those experiences being adverse. Typically, however, sensitive risk factor screening in pregnancy is predominantly focussed on risk associated with the mother rather than the broader environment for the child/ren.

Smoking in pregnancy was correlated with substance misuse, both in the mother and also their partner/family. There is increasing evidence from animal, and now human studies that smoking, particularly when commenced in adolescence for females, is a precursor to subsequent alcohol and other drug misuse, and also that concurrent smoking amplifies the negative health impacts of alcohol and other drug misuse (see for example Cross et al [34]).

Not living with another adult (rather than a reported lack of support) was associated with domestic violence and unstable relationships, and major maternal mental health conditions. Recent studies have highlighted the relationship between women’s mental health, experience of domestic/intimate partner violence and unstable housing, homelessness and isolation [35, 36]. Maternal anxious mood in the two weeks prior to screening was, as expected, correlated with anxiety and depression. The screening questions used the Matthey General Mood Questionnaire, which has been demonstrated to have better concordance with DSM anxiety disorder than other (more lengthy and intrusive) measures such as the Edinburgh Depression Scale, or Hospital Anxiety and Depression Scale [30, 37]. The study population could have thus been expected to include a high prevalence of mothers with anxiety.

Interestingly, being a young mother (aged <23), a recruitment criterion for other commonly implemented home visiting programs (see for example Roblings et al Building blocks [38]), was very weakly associated with only maternal experience of domestic violence, and thus may not, in this population, be a sufficient indicator of the need for additional support. Poverty (notably more-so than never having had a job) as determined by receipt of state benefits, which is another common home visiting eligibility criterion (see Home Visiting Evidence of Effectiveness–HomVEE [39]), was associated with domestic violence and involvement with child protection services, and substance misuse in the partner or family (but not the mother). The association between non-completion of secondary education and less disclosure of maternal anxiety, depression and mental health conditions was unexpected. Further research is needed to understand this association, particularly as poorer maternal education is reported in many studies to be associated with poor child health and development outcomes [40].

Limitations

These results cannot be generalized to population prevalence as the data were limited to those women who disclosed two or more screened-for sociodemographic factors in the context of recruitment for a sustained nurse home visiting trial. Also, disclosure information was obtained from retrospective audit by the nurses, and reliant on the quality of their documentation and/or recall and may not have been comprehensive. The nurses did not note whether the disclosures were directly reported by the mother and/or observed by the nurse, and no independent verification of the noted risks (for example, mental health diagnosis confirmation) were sought by the researchers. However, a large number of serious risks were identified consistent with the expected vulnerabilities within a population who could benefit from sustained and intensive support. It is also possible that the intervention may have prevented or mitigated risks, such that the prevalence reported here, albeit high, may underestimate that of a non-intervention population at risk. The correlations between individual screening criteria and disclosed risks were small.

Conclusion

Children’s exposure to ACEs has been recognized by WHO as a significant public health issue. This study showed a high prevalence of ACE risks in the screened population who received the right@home visiting intervention and demonstrated small, albeit significant patterns of correlations between individual sociodemographic screening factors and disclosed risks. Sociodemographic screening in pregnancy was undertaken using non-sensitive questions that women were comfortable to answer in a public waiting room and identified this high risk population. Certain screened risks were correlated with a number of ACE risk disclosures in this population, with maternal smoking in pregnancy and not living with another adult correlated with multiple ACE risks. Young maternal age was not correlated with the disclosed risks, however, receipt of state benefits (poverty) was correlated with elements of complex family environments; domestic violence, family substance misuse and involvement with child protection services. Although the correlations were significant but weak, screening for these characteristics may reduce dependence on the unreliability of maternal risk disclosure in first or minimal contact screening, and enhance identification of families to engage in interventions to prevent negative consequences of children’s exposure to adverse experiences.

Supporting information

S1 Checklist. STROBE statement—Checklist of items that should be included in reports of cohort studies.

(DOC)

Acknowledgments

The “right@home” sustained nurse home visiting trial is a research collaboration between the Australian Research Alliance for Children and Youth (ARACY); the Translational Research and Social Innovation (TReSI) Group at Western Sydney University; and the Centre for Community Child Health (CCCH), which is a department of The Royal Children’s Hospital and a research group of Murdoch Children’s Research Institute. We thank all families, the research assistants, and nurses and social care practitioners who worked on the right@home trial, the antenatal clinic staff at participating hospitals who helped facilitate the research, and the Expert Reference Group for their guidance in designing the trial. The MECSH® program is a registered trademark of UNSW Australia and Western Sydney University is the authorised licence holder.

Data Availability

Data cannot be shared publicly because they contain sensitive participant information which are restricted to use for research purposes only. This restriction is in accordance with the Participant Information and Consent Form and approved study protocol, governed by the Royal Children’s Hospital Human Research Ethics Committee (HREC 32296). We invite researchers to request access to the data from the Melbourne Children's Campus LifeCourse institutional data access platform (https://lifecourse.melbournechildrens.com/data-access/) or the governing Royal Children’s Hospital HREC (https://www.rch.org.au/ethics/).

Funding Statement

This work is supported by the Victorian Department of Education and Early Childhood Development, the Tasmanian Department of Health, the Ian Potter Foundation, Sabemo Trust, Sidney Myer Fund, the Vincent Fairfax Family Foundation, and the National Health and Medical Research Council (NHMRC, 1079418). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Felitti VJ, Anda RF, Nordenberg D, Williamson DF, Spitz AM, Edwards V, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: The adverse childhood experiences (ACE) study. Am J Prev Med. 1998;14(4):245–58. doi: 10.1016/S0749-3797(98)00017-8 [DOI] [PubMed] [Google Scholar]
  • 2.Bright MA, Knapp C, Hinojosa MS, Alford S, Bonner B. The comorbidity of physical, mental, and developmental conditions associated with childhood adversity: a population based study. Matern Child Health J. 2016;20(4):843–53. doi: 10.1007/s10995-015-1915-7 [DOI] [PubMed] [Google Scholar]
  • 3.Shonkoff JP, Garner AS, Siegel BS, Dobbins MI, Earls MF, McGuinn L, et al. The lifelong effects of early childhood adversity and toxic stress. Pediatrics. 2012;129(1):e232–e46. doi: 10.1542/peds.2011-2663 [DOI] [PubMed] [Google Scholar]
  • 4.Siegel BS, Dobbins MI, Earls MF, Garner AS, Pascoe J, Wood DL, et al. Early childhood adversity, toxic stress, and the role of the pediatrician: Translating developmental science into lifelong health. Pediatrics. 2012;129(1):e224–e31. doi: 10.1542/peds.2011-2662 [DOI] [PubMed] [Google Scholar]
  • 5.Sonu S, Post S, Feinglass J. Adverse childhood experiences and the onset of chronic disease in young adulthood. Prev Med. 2019;123:163–70. doi: 10.1016/j.ypmed.2019.03.032 [DOI] [PubMed] [Google Scholar]
  • 6.Szilagyi M, Kerker BD, Storfer-Isser A, Stein REK, Garner A, O’Connor KG, et al. Factors associated with whether pediatricians inquire about parents’ adverse childhood experiences. Acad Pediatr. 2016;16(7):668–75. doi: 10.1016/j.acap.2016.04.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Rollans M, Schmied V, Kemp L, Meade T. Negotiating policy in practice: Child and family health nurses’ approach to the process of postnatal psychosocial assessment. BMC Health Serv Res. 2013;13(1). doi: 10.1186/1472-6963-13-133 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Williams CJ, Turner KM, Burns A, Evans J, Bennert K. Midwives and women’s views on using UK recommended depression case finding questions in antenatal care. Midwifery. 2016;35:39–46. doi: 10.1016/j.midw.2016.01.015 [DOI] [PubMed] [Google Scholar]
  • 9.Rollans M, Schmied V, Kemp L, Meade T. Digging over that old ground: An Australian perspective of women’s experience of psychosocial assessment and depression screening in pregnancy and following birth. BMC Womens Health. 2013;13(1). doi: 10.1186/1472-6874-13-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Dauber S, John T, Hogue A, Nugent J, Hernandez G. Development and implementation of a screen-and-refer approach to addressing maternal depression, substance use, and intimate partner violence in home visiting clients. Child Youth Serv Rev. 2017;81:157–67. doi: 10.1016/j.childyouth.2017.07.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Leis JA, Mendelson T, Perry DF, Tandon SD. Perceptions of mental health services among low-income, perinatal African-American Women. Womens Health Issues. 2011;21(4):314–9. doi: 10.1016/j.whi.2011.03.005 [DOI] [PubMed] [Google Scholar]
  • 12.Johnson K, Woodward A, Swenson S, Weis C, Gunderson M, Deling M, et al. Parents’ adverse childhood experiences and mental health screening using home visiting programs: A pilot study. Public Health Nurs. 2017;34(6):522–30. doi: 10.1111/phn.12345 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Spangaro J, Koziol-McLain J, Zwi A, Rutherford A, Frail MA, Ruane J. Deciding to tell: Qualitative configurational analysis of decisions to disclose experience of intimate partner violence in antenatal care. Soc Sci Med. 2016;154:45–53. doi: 10.1016/j.socscimed.2016.02.032 [DOI] [PubMed] [Google Scholar]
  • 14.Chisholm CA, Bullock L, Ferguson JEJ II. Intimate partner violence and pregnancy: screening and intervention. Am J Obstet Gynecol. 2017;217(2):145–9. doi: 10.1016/j.ajog.2017.05.043 [DOI] [PubMed] [Google Scholar]
  • 15.World Health Organization. Responding to Intimate Partner Violence and Sexual Violence Against Women: WHO Clinical and Policy Guidelines. Geneva: WHO; 2013. [PubMed] [Google Scholar]
  • 16.Cowley S, Whittaker K, Malone M, Donetto S, Grigulis A, Maben J. Why health visiting? Examining the potential public health benefits from health visiting practice within a universal service: A narrative review of the literature. Int J Nurs Stud. 2015;52(1):465–80. [DOI] [PubMed] [Google Scholar]
  • 17.Peckover S, Aston M. Examining the social construction of surveillance: A critical issue for health visitors and public health nurses working with mothers and children. J Clin Nurs. 2018;27(1–2):e379–e89. doi: 10.1111/jocn.14014 [DOI] [PubMed] [Google Scholar]
  • 18.Vanderburg S, Wright L, Boston S, Zimmerman G. Maternal child home visiting program improves nursing practice for screening of woman abuse. Public Health Nurs. 2010;27(4):347–52. doi: 10.1111/j.1525-1446.2010.00865.x [DOI] [PubMed] [Google Scholar]
  • 19.Schaefer JK. Personal characteristics of effective home visitors. J Soc Serv Res. 2016;42(1):84–95. doi: 10.1080/01488376.2015.1078868 [DOI] [Google Scholar]
  • 20.Buek KW, Lakey DL, Mandell DJ. Paternity establishment at birth and early maltreatment: Risk and protective effects by maternal race and ethnicity. Child Abuse Negl. 2019;95. doi: 10.1016/j.chiabu.2019.104069 [DOI] [PubMed] [Google Scholar]
  • 21.Lanier P, Jonson-Reid M. Comparing primiparous and multiparous mothers in a nurse home visiting prevention program. Birth. 2014;41(4):344–52. doi: 10.1111/birt.12120 [DOI] [PubMed] [Google Scholar]
  • 22.Rose GA. Rose’s Strategy of Preventive Medicine: the complete original text. New ed. Khaw K-T, Marmot MG, Rose GA, editors. Oxford: Oxford University Press; 2008. [Google Scholar]
  • 23.Goldfeld S, Price A, Bryson H, Bruce T, Mensah F, Orsini F, et al. ‘right@home’: a randomised controlled trial of sustained nurse home visiting from pregnancy to child age 2 years, versus usual care, to improve parent care, parent responsivity and the home learning environment at 2 years. BMJ Open. 2017;7(3):e013307. doi: 10.1136/bmjopen-2016-013307 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Price AM, Bryson HE, Mensah F, Kemp L, Bishop L, Goldfeld S. The feasibility and acceptability of a population-level antenatal risk factor survey: Cross-sectional pilot study. J Paediatr Child Health. 2017;53(6):572–7. Epub 2017/04/04. doi: 10.1111/jpc.13510 [DOI] [PubMed] [Google Scholar]
  • 25.Goldfeld S, Price A, Kemp L. Designing, testing, and implementing a sustainable nurse home visiting program: right@home. Ann N Y Acad Sci. 2018;1419(1):141–59. doi: 10.1111/nyas.13688 [DOI] [PubMed] [Google Scholar]
  • 26.Kemp L. Adaptation and fidelity: A recipe analogy for achieving both in population scale implementation. Prev Sci. 2016;17(4):429–38. doi: 10.1007/s11121-016-0642-7 [DOI] [PubMed] [Google Scholar]
  • 27.Kemp L, Harris E, McMahon C, Matthey S, Vimpani G, Anderson T, et al. Child and family outcomes of a long-term nurse home visitation program: a randomised controlled trial. Arch Dis Child. 2011;96(6):533–40. doi: 10.1136/adc.2010.196279 [DOI] [PubMed] [Google Scholar]
  • 28.Goldfeld S, Price A, Smith C, Bruce T, Bryson H, Mensah F, et al. Nurse home visiting for families experiencing adversity: A randomized trial. Pediatrics. 2019;143(1):e20181206. doi: 10.1542/peds.2018-1206 [DOI] [PubMed] [Google Scholar]
  • 29.Sanson AV, Hawkins MT, Misson S. The development and validation of Australian indices of child development -Part II: Validity support. Child Indic Res. 2010;3(3):293–312. doi: 10.1007/s12187-009-9049-3 [DOI] [Google Scholar]
  • 30.Matthey S, Valenti B, Souter K, Ross-Hamid C. Comparison of four self-report measures and a generic mood question to screen for anxiety during pregnancy in English-speaking women. J Affect Disord. 2013;148(2–3):347–51. doi: 10.1016/j.jad.2012.12.022 [DOI] [PubMed] [Google Scholar]
  • 31.WAVE Trust. 70/30 national campaign: 70% reduction in child abuse and neglect by the year 2030. Available from: http://www.70-30.org.uk. Cited 23 Jul 2019.
  • 32.Michalopoulos C, Lee H, Duggan A, Lundquist E, Tso A, Crowne S, et al. The Mother and Infant Home Visiting Program Evaluation: Early Findings on the Maternal, Infant, and Early Childhood Home Visiting Program. Washington, DC: Office of Planning, Research and Evaluation, Administration for Children and Families, U.S. Department of Health and Human Services, 2015. [Google Scholar]
  • 33.Kardamanidis K, Kemp L, Schmied V. Uncovering psychosocial needs: perspectives of Australian child and family health nurses in a sustained home visiting trial. Contemp Nurs. 2009;33(1):50–8. doi: 10.5172/conu.33.1.50 [DOI] [PubMed] [Google Scholar]
  • 34.Cross SJ, Lotfipour S, Leslie FM. Mechanisms and genetic factors underlying co-use of nicotine and alcohol or other drugs of abuse. Am J Drug Alcohol Abuse. 2017;43(2):171–85. doi: 10.1080/00952990.2016.1209512 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Jones TM, Nurius P, Song C, Fleming CM. Modeling life course pathways from adverse childhood experiences to adult mental health. Child Abuse Negl. 2018;80:32–40. doi: 10.1016/j.chiabu.2018.03.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Adams EN, Clark HM, Galano MM, Stein SF, Grogan-Kaylor A, Graham-Bermann S. Predictors of housing instability in women who have experienced intimate partner violence. J Interpers Violence. 2021;36(7–8):3459–81. doi: 10.1177/0886260518777001 [DOI] [PubMed] [Google Scholar]
  • 37.Matthey S, Bilbao F. A comparison of the PHQ-2 and MGMQ for screening for emotional health difficulties during pregnancy. J Affect Disord. 2018;234:174–9. doi: 10.1016/j.jad.2018.02.069 [DOI] [PubMed] [Google Scholar]
  • 38.Robling M, Bekkers MJ, Bell K, Butler CC, Cannings-John R, Channon S, et al. Effectiveness of a nurse-led intensive home-visitation programme for first-time teenage mothers (Building Blocks): A pragmatic randomised controlled trial. Lancet. 2016;387:146–55. doi: 10.1016/S0140-6736(15)00392-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.US Department of Health and Human Services. Home Visiting Evidence of Effectiveness 2014. Available from: http://homvee.acf.hhs.gov. Cited 23 Jul 2019.
  • 40.Walker SP, Wachs TD, Grantham-Mcgregor S, Black MM, Nelson CA, Huffman SL, et al. Inequality in early childhood: Risk and protective factors for early child development. Lancet. 2011;378(9799):1325–38. doi: 10.1016/S0140-6736(11)60555-2 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

George Vousden

9 Sep 2021

PONE-D-21-06995Identification of families in need of support: correlates of adverse childhood experiences in the right@home sustained nurse home visiting programPLOS ONE

Dear Dr. Kemp,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please note that as per our publication criteria, PLOS ONE requires that all experiments, statistics and other analyses are performed to a high technical standard, described in sufficient detail and adhere to appropriate reporting guidelines and community standards. Conclusions must be presented in an appropriate fashion and be supported by the data (Please see http://journals.plos.org/plosone/s/criteria-for-publication).

Your manuscript has been assessed by two reviewers who have raised overlapping concerns with the statistical analysis performed and ability of the results to support your conclusions. The reviewers have clearly outlined these concerns so I will not repeat them here. However, I do encourage you to carefully revise your conclusions of the manuscript in light of the concerns raised; statistical significance should not be equated with effect size - as you note in your results section all significant correlations reported in your manuscript were weak. It is therefore not appropriate to indicate that 'Smoking in pregnancy was particularly correlated with substance misuse' (line 264) or indicate that variables shown to have statistical significant association act as a proxy for one another (conclusions). Please bear this in mind as you carefully revise your manuscript to respond to all of the reviewer's concerns.

Please submit your revised manuscript by Oct 23 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

George Vousden

Division Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following in the Financial Disclosure section: "This work is supported by the Victorian Department of Education and Training, the Tasmanian Department of Health and Human Services, the Ian Potter Foundation, Sabemo Trust, Sidney Myer Fund, the Vincent Fairfax Family Foundation, and the National Health and Medical Research Council (NHMRC, 1079418). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

We note that you received funding from a commercial source: Ian Potter Foundation and Sabemo Trust

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc. 

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. 

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

4. Your abstract cannot contain citations. Please only include citations in the body text of the manuscript, and ensure that they remain in ascending numerical order on first mention.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Important note: This review pertains only to ‘statistical aspects’ of the study and so ‘clinical aspects’ [like medical importance, relevance of the study, ‘clinical significance and implication(s)’ of the whole study, etc.] are to be evaluated [should be assessed] separately/independently. Further please note that any ‘statistical review’ is generally done under the assumption that (such) study specific methodological [as well as execution] issues are perfectly taken care of by the investigator(s). This review is not an exception to that and so does not cover clinical aspects {however, seldom comments are made only if those issues are intimately / scientifically related & intermingle with ‘statistical aspects’ of the study}. Agreed that ‘statistical methods’ are used as just tools here, however, they are vital part of methodology [and so should be given due importance].

COMMENTS: Though the use of non-parametric Spearman’s ‘Correlation coefficient (ρ)’ {instead of parametric ‘Pearson’s} is appreciated, as most of measures/tools used are [though appropriate] yield data that are in ‘ordinal’ level of measurement and then application of suitable non-parametric test(s) is/are indicated/advisable even if distribution may be ‘Gaussian’ (i.e., normal)]. Moreover, most of the ‘Spearman correlation Coefficients’ reported in Table 3 [Spearman correlations of screening criteria by disclosed to MECSH nurse] are numerically very small {though sometimes significant}. In this context, please read the following:

Statistical test usually used to assess significance of Pearson’s ‘Correlation coefficient (r)’ is ‘t’ [where t = { r � [(n-2) / (1-r2)] }for df=n-2, n is sample size] and here Ho is that the population/standard value of ‘r’ is zero. You need r=0.878 to be significant at 5% when n=5 but you need r=0.273 only, if n=50 & you need r=0.088 only, if n=500. Because ‘P-value’ heavily depends on sample size, it is customary to use the (available in most text books on ‘Biostatistics’ or on ‘www/net’) guidelines very strongly suggesting] to consider an absolute value of ‘Correlation coefficient for interpreting positive or negative correlations (and do not rely only on corresponding ‘P’-value but also consider an absolute value of ‘Correlation coefficient’). [This argument is equally applicable to non-parametric Spearman’s ‘Correlation coefficient (ρ)’ as well.]

This is pasted from one standard textbook on ‘Research Methodology’ and I am sure that the authors already know these things, however, it is very essential to keep the limitations in mind while interpreting results. In fact, I wonder “how even ‘Spearman’s Correlation coefficients (ρ)s’ are calculated as most of the variables are (seems to be as per lines 167-8: Spearman correlations were conducted to test the association between the presence/absence of screening factors and presence/absence of disclosed ACE risks.) ‘binary/dichotomous’ [where only biserial or point biserial correlation coefficients are appropriate”. Will you please explain? (may be correctly done, but explanation is essential).

Major part (lines 309-317: In this population, maternal smoking in pregnancy could be considered to be acting as a proxy for substance misuse, involvement with child protection services, mental health issues and family violence, suggesting that in similar populations particular consideration be given to additional and sustained support for mothers who are smoking in pregnancy. Not living with another adult was a proxy for unstable and violent relationships and major mental health issues; and anxious mood in the weeks prior to screening in pregnancy as a proxy for anxiety/depression and mental health issues during the subsequent two years. Maternal age was not a useful indicator of risk, however, receipt of state benefits was a proxy for a complex family environment) of ‘conclusion’ section is not really a [rather may/cannot be the] part of conclusion. Opinion(s) [may be even if learned from this experience], in my opinion, are not to be included in ‘conclusions’ of the study.

Overall, the presentation is confusing with respect few points {example – lines 139-140: 363 women were allocated to the trial intervention arm, and 352 commenced the intervention program what is the relevance of such grouping? No group comparison is clearly seen anywhere later. How the ‘allocation’ was performed is not given. Moreover, at few places {example - lines 167-8: Spearman correlations were conducted to test the association between the presence/absence of screening factors and presence/absence of disclosed ACE risks as we never conduct the correlations} construction of a sentence needs to be checked, I guess.

Limitations of the study are not discussed in a separate section (expected). Lines 295-97 mention only one limitation [These results cannot be generalized to population prevalence as the data were limited to those women who disclosed two or more screened-for sociodemographic factors in the context of recruitment for a sustained nurse home visiting trial.] though, which is not enough. {Does that mean {according to authors} there are none?} In my opinion, though it is a straight-forward simple study (not many methodological issues), contributes a marginal/minimal.

As pointed out in ‘important note’ above “This review pertains only to ‘statistical aspects’ of the study and so ‘clinical aspects’ should be assessed separately/independently. In my opinion, to rescue this article (which is difficult but not impossible), lot of re-vision is needed. Therefore, just short of ‘rejection’, I am recommending “Major Revision”.

Reviewer #2: PLOS One

PONE-D-21-06995

The purpose of this manuscript was to examine the association between sociodemographic measures collected at entry to a home visiting program and risks were identified based on disclosures to the nurse and measured in subsequent nurse case files. Screening was reported by the mother at the antenatal clinic and risks were identified by nurses through a retrospective case audit following HV services up to age 2 years of the child. This unique dataset explores an important topic in the field. However, I came away with totally different interpretation of the data presented. Specifically, the very weak associations (although statistically significant) between screening measures and subsequent risks imply that these are not good measures from a sensitivity/specificity perspective in identifying families who may benefit from sustained home visiting.

The introduction overall is well-written and clear. The authors capture the main issues the field is grappling with. The authors make a compelling case that a non-sensitive screening tool with high specificity would be ideal for many reasons. I also suggest the authors cite work in the US that utilized data from birth certificates that are highly predictive of later child maltreatment. However, I am not sure that the items in the screening tool presented here are actually non-sensitive since they include socially stigmatized domains such as poverty, maternal smoking, and mental health concerns that at least in most “Western” contexts would be subject social desirability.

There is another limitation to the approach that is not considered, it appears that the ACEs are risks disclosed to the nurse, while the screening tool is self-reported by the mother. It is not clear whether these disclosures had to be reported directly from the mother to the nurse, or if the nurse could observe a risk and this counts as a disclosure. For example, if a nurse knew that a family was involved with CPS but the mother never disclosed this detail, how would the nurse document this in the spreadsheet? We then wade into territory regarding subjective/objective assessments and agreement between different reporters. But this is a fairly minor issue.

The major concern regards the “weak” correlations, as stated by the authors. In the conclusions the authors provide an interpretation that since the association between smoking and substance misuse was .273, that this is “particularly correlated”. I would disagree. Similar the correlated between anxious mood and anxiety was .186, this is quite a weak association. It is then suggested that these are now “proxies” for actual risks which to me is a very dangerous conclusion. Although the stakes in false-positives or negatives for this type of prediction are low (worst case you get offered a home visiting program), we should not equate a low association with a valid predictor.

I was also curious why multivariable models were not used to see how screening measures predicted risks, while controlling for all of these factors, but perhaps this was not the goal of the research.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: renamed_592f5.docx

PLoS One. 2022 Oct 3;17(10):e0275423. doi: 10.1371/journal.pone.0275423.r002

Author response to Decision Letter 0


23 Jan 2022

We would like to thank the editor and reviewers for their helpful and constructive review of our paper. We have documented our responses in the covering letter file, which includes a table of our responses for each reviewer's comments. Thank you.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Jianhong Zhou

8 Jul 2022

PONE-D-21-06995R1Identification of families in need of support: correlates of adverse childhood experiences in the right@home sustained nurse home visiting programPLOS ONE

Dear Dr. Kemp,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Specifically, we require that conclusions are presented in an appropriate fashion and are supported by the data. We still have concerns about some of the statements in your conclusion. For instance, you indicate that "Smoking in pregnancy was particularly correlated with substance misuse" (line 256). We would suggest removing "particularly" in this case as only weak correlation is reported and we feel your data does not support the conclusion here. In addition, you indicate that "Sociodemographic screening in pregnancy using non-sensitive questions in this study appropriately identified a population of families with risks for ACEs, for whom sustained home visiting support may be of benefit to mediate the impact of risk and improve outcomes." (line 313-315). We do not feel this is supported by your data -  only (weakly) correlation was presented for the sociodemographic characteristics with ACEs, and that does not "identify" population of families with risks for ACEs. Please ensure that all the statements in Conclusion are supported by your data presented and not overstate your conclusions.Finally, please provide your responses to the first reviewer's comments below.

Please submit your revised manuscript by Jul 25 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Jianhong Zhou

Staff Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following in your Competing Interests section:  

"The MECSH® program is a registered trademark of UNSW Australia and from 2016 for the duration of 5 years is being sublicensed to Western Sydney University."

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now 

 This information should be included in your cover letter; we will change the online submission form on your behalf.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: COMMENTS: Since all of the comments made on earlier draft by me (and hopefully by other respected reviewers also) were/are attended positively, I recommend the acceptance because the manuscript now has achieved acceptable level, in my opinion.

Nevertheless, I wish/want to let authors note that, even if [while the assessment of correlation in dichotomous vs dichotomous case] Pearson’s r, Spearman’s Rho, and Phi all produce the same results {though the SPSS output they have kindly provided, are not visible}, always report the most applicable ones. And also note that figure(s) not [always] the substitute of table(s). They are, generally, not ‘alternatives’ but ‘complementary’.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Dr. Sanjeev Sarmukaddam

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 2

Jianhong Zhou

19 Sep 2022

Identification of families in need of support: correlates of adverse childhood experiences in the right@home sustained nurse home visiting program

PONE-D-21-06995R2

Dear Dr. Kemp,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Jianhong Zhou

Staff Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Jianhong Zhou

22 Sep 2022

PONE-D-21-06995R2

Identification of families in need of support: correlates of adverse childhood experiences in the right@home sustained nurse home visiting program

Dear Dr. Kemp:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Jianhong Zhou

Staff Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. STROBE statement—Checklist of items that should be included in reports of cohort studies.

    (DOC)

    Attachment

    Submitted filename: renamed_592f5.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    Data cannot be shared publicly because they contain sensitive participant information which are restricted to use for research purposes only. This restriction is in accordance with the Participant Information and Consent Form and approved study protocol, governed by the Royal Children’s Hospital Human Research Ethics Committee (HREC 32296). We invite researchers to request access to the data from the Melbourne Children's Campus LifeCourse institutional data access platform (https://lifecourse.melbournechildrens.com/data-access/) or the governing Royal Children’s Hospital HREC (https://www.rch.org.au/ethics/).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES